Elevance Health (ELV) Earnings Date & Reports

Key Takeaways

• Elevance Health reported adjusted EPS of $7.45, surpassing the consensus estimate of $6.21 by roughly 20%.
• Operating revenue reached $49.8 billion, up 0.8% year-over-year and ahead of Wall Street forecasts of approximately $48.8 billion.
• Approximately $0.80 per share of the earnings beat stemmed from non-recurring below-the-line benefits, primarily net investment income valuation adjustments, raising questions about earnings quality.
• Full-year 2026 adjusted EPS guidance was raised to at least $27.00, while operating cash flow guidance was lifted to at least $6.0 billion.
• Despite the headline beat, shares fell 10.58% to $381.62, as investors focused on persistent Medicaid margin pressure and a declining medical membership base.

Earnings Context and Why It Matters

Elevance Health's second-quarter 2026 results, released on July 15, arrived at a pivotal moment for the managed care giant. The company has been navigating elevated medical cost trends in its government businesses, membership attrition in key lines including Medicaid and Medicare Advantage, and ongoing pressure on operating margins. Coming off a Q1 2026 that saw net income decline 19.2% year-over-year, investors were looking for signs of stabilization. This quarter's results offered a mixed picture: headline numbers that significantly exceeded consensus, yet underlying metrics that revealed continued structural challenges. As one of the largest health benefits companies in the United States, Elevance's results serve as a bellwether for the broader managed care sector, making the market's skeptical reaction particularly notable.

Reported Results

Elevance Health posted second-quarter 2026 operating revenue of $49.8 billion, an increase of 0.8% from $49.4 billion in the prior-year quarter and above the consensus estimate of roughly $48.8 billion. Revenue growth was driven by higher premium yields in the Health Benefits segment and expanded CarelonRx product revenue, partially offset by anticipated membership declines across Medicare Advantage, Medicaid, and Employer Group risk lines.

On the earnings front, the company reported diluted EPS (earnings per share) of $6.71 and adjusted diluted EPS of $7.45, the latter easily clearing the Zacks Consensus Estimate of $6.18 and the broader consensus of $6.21. However, approximately $0.80 of that adjusted EPS came from net below-the-line benefits, primarily tied to investment income valuation adjustments. Excluding this non-recurring boost, the operational beat was narrower than the headline suggested.

The benefit expense ratio — a key measure of medical costs relative to premiums — came in at 89.7%, up 80 basis points from 88.9% a year ago. While this was better than internal expectations, it still reflects elevated medical cost trends in government programs. The adjusted operating expense ratio rose 100 basis points to 11.0%, contributing to a decline in adjusted operating margin from 5.0% to 3.6%. Days in Claims Payable, a measure of claims payment speed and reserve adequacy, stood at 45.4 days as of June 30, 2026.

Medical membership totaled approximately 44.9 million, down 469,000 sequentially, driven by a known commercial fee-based customer transition and anticipated attrition in Individual ACA (Affordable Care Act) and Medicaid populations. Health Benefits segment operating revenue reached $42.7 billion, while Carelon — comprising CarelonRx and Carelon Services — generated $19.2 billion in operating revenue, up 6% year-over-year.

AI Screener

For investors tracking earnings-driven stock movements like Elevance Health's post-report decline, Tickeron's AI Screener offers a powerful way to stay ahead of market trends. The AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that allows traders and investors to filter thousands of securities using customizable criteria such as industry classification, market capitalization, technical indicators, price patterns, volatility metrics, and AI-driven trading signals. Whether scanning for breakout candidates, earnings-related volatility setups, or fundamentally strong names under temporary pressure, the screener helps users identify trade ideas and market opportunities more efficiently than manual research alone. Explore the AI Screener to uncover your next actionable insight.

Market Reaction and Investor Sentiment

Despite delivering results that significantly surpassed consensus estimates, Elevance Health shares tumbled 10.58% on July 15, closing at $381.62 compared to the prior close of $426.79. The sharp selloff reflected investor skepticism about the quality of the earnings beat. With roughly $0.80 per share attributable to non-recurring items, the underlying operational performance was less impressive than the headline suggested. The market also focused on persistent Medicaid margin pressure, the 26.9% year-over-year decline in adjusted operating gain to $1.8 billion, and the sequential membership erosion. The fact that management raised full-year adjusted EPS guidance by only $0.25 — to at least $27.00 — despite the substantial Q2 beat reinforced concerns that much of the quarterly outperformance was one-time in nature and not reflective of sustainably improved fundamentals.

Forward Outlook and Key Factors to Monitor

Looking ahead, several factors will shape Elevance Health's trajectory through the remainder of fiscal 2026 and into 2027. First, investors should closely track the benefit expense ratio. While Q2's 89.7% reading came in better than expected, elevated medical cost trends in government programs remain a headwind. Any further deterioration could pressure margins beyond what the company has already guided.

Second, membership trends will be critical. The sequential loss of 469,000 members — driven by Medicaid redeterminations, Individual ACA attrition, and a commercial fee-based customer transition — warrants monitoring. Stabilization in these membership lines would be a positive signal, particularly in the higher-margin commercial segments.

Third, Carelon's growth trajectory is an important offset to Health Benefits margin compression. With Carelon operating revenue up 6% year-over-year and improving specialty pharmacy profitability, continued expansion in Carelon Services' risk-based solutions could provide a more durable earnings stream over time.

Fourth, capital deployment remains a supportive factor. The company repurchased 0.7 million shares for $234 million during the quarter and has approximately $5.3 billion remaining under its share repurchase authorization. Combined with a quarterly dividend of $1.72 per share, Elevance continues to return significant capital to shareholders. Finally, management's commitment to returning to at least 12% adjusted EPS growth in 2027 off the 2026 baseline offers a concrete medium-term benchmark against which investors can measure progress.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations